EZH2 and T-cell non-Hodgkin lymphoma: In the present study, we have revealed that pharmacological EZH2 inhibition is not suitable in combination with chemotherapeutic oxaliplatin which is commonly used in the second-line treatment of mature T-cell lymphomas.